New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin);  ;  ; leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) - injection with diluent - 22.5 mg - active: leuprorelin acetate 22.5mg (includes 28.2mg leuprorelin acetate to deliver 22.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 22.5mg (includes 29.2mg leuprorelin acetate to deliver 22.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 45 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.,central precocious puberty (cpp),eligard 45mg 6 month is indicated for the treatment of children 2 years of age and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - prostate cancer,eligard 7.5mg 1 month, eligard 22.5mg 3 month, eligard 30mg 4 month and eligard 45mg 6 month are indicated for the:,? palliative treatment of advanced prostate cancer.,? treatment of high-risk localised and locally advanced hormone-dependent prostate cancer in combination with radiotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: polyglactin; n-methyl-2-pyrrolidone - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - leuprorelin acetate, quantity: 22.5 mg - injection, modified release - excipient ingredients: n-methyl-2-pyrrolidone; polyglactin - bicalutamide,treatment of advanced prostate cancer in combination with lhrh agonist therapy.,leuprorelin,eligard? is indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin);  ;  ; leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) - injection with diluent - 45 mg - active: leuprorelin acetate 45mg (includes 56.3mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 45mg (includes 59.2mg leuprorelin acetate to deliver 45mg leuprorelin actate equiv to 42mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

mundipharma new zealand ltd - leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin);  ;  ; leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) - injection with diluent - 7.5 mg - active: leuprorelin acetate 7.5mg (includes 10.2mg leuprorelin acetate to deliver 7.5mg leuprorelin)     excipient: n-methyl-2-pyrrolidone polyglactin active: leuprorelin acetate 7.5mg (includes 10.6mg leuprorelin acetate to deliver 7.5mg leuprorelin) excipient: n-methyl-2-pyrrolidone polyglactin - indicated for the palliative treatment of advanced prostate cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin - subcutaneous implant - 3.6 mg - active: leuprorelin acetate 3.78mg equivalent to 3.6 mg leuprorelin excipient: polyglactin - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg - subcutaneous implant - 5 mg - active: leuprorelin acetate 5.25mg equivalent to leuprorelin 5 mg excipient: poly(lactide) - palliative treatment of patients with advanced, hormone-dependent prostate carcinoma